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ABSTRACT 
 
Subcutaneous (SC) injection is becoming a more common route for the administration of 
biopharmaceuticals. Currently, there is no reliable in vitro method that can be used to 
anticipate the in vivo performance of a biopharmaceutical formulation intended for SC 
injection. Nor is there an animal model that can predict in vivo outcomes such as 
bioavailability in humans. We address this unmet need by the development of a novel in 
vitro system, termed Scissor (Subcutaneous Injection Site Simulator). The system models 
environmental changes that a biopharmaceutical could experience as it transitions from 
conditions of a drug product formulation to the homeostatic state of the hypodermis 
following SC injection. Scissor uses a dialysis-based injection chamber, which can 
incorporate various concentrations and combinations of acellular extracellular matrix 
(ECM) components that may affect the release of a biopharmaceutical from the SC 
injection site. This chamber is immersed in a container of a bicarbonate-based 
physiological buffer that mimics the SC injection site and the infinite sink of the body, 
respectively. Such an arrangement allows for real-time monitoring of the 
biopharmaceutical within the injection chamber that can be used to characterize 
physicochemical changes of the drug and its interactions with ECM components. 
Movement of a biopharmaceutical from the injection chamber to the infinite sink 
compartment simulates the drug migration from the injection site and uptake by the 
blood and/or lymph capillaries. Here, we present an initial evaluation of the Scissor 
system using the ECM element hyaluronic acid and test formulations of insulin and four 
different monoclonal antibodies. Our findings suggest that Scissor can provide a 
tractable method to examine the potential fate of a biopharmaceutical formulation 
after its SC injection in humans and that this approach may provide a reliable and 
representative alternative to animal testing for the initial screening of SC formulations.  
 
INTRODUCTION 
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More than forty years after the innovative application of recombinant DNA technology to 
produce novel protein therapeutics, the biotechnology industry has fulfilled its promise 
of safely and effectively treating unmet medical needs and providing life saving 
therapies.  Indeed, many diseases can now be treated as a chronic condition rather than 
an acute malady with a poor prognosis 1. As these is strong patient preference for 
subcutaneous (SC) injections over the more time-intensive intravenous (IV) infusion 
therapies 2, many biopharmaceuticals under development as well as those previously 
approved as IV therapies are being formulated for SC injection. While IV administration 
is considered to consistently provide the optimal means of delivering the entirety of a 
dose to a patient, molecules dosed by the SC route typically have a lower 
bioavailability. Currently, it is impossible to predict the extent of this diminished 
bioavailability and to determine the basis for these outcomes; the biophysical status of 
a SC injected protein or peptide and its possible interactions with ECM components of 
the hypodermis in man are not easily monitored. What is known is that currently 
approved biopharmaceutical formulations have bioavailabilities that range from 20 – 100 
% 3, depending on the drug, with published data on the bioavailablity of monoclonal 
antibodies in man suggests absorption between 50-100% 4. Efforts to find animal models 
that universally and reliably predict human SC bioavailabilities have been unsuccessful 5. 
For example, the SC bioavailability of human epoetin-β is 80% in dogs, 76% in rats, and 
70% in mice 6 but only 20-36% in man 7,8; interferon-α has a 42% BA in dogs 9 but >80% in 
man 10 following SC injection.   
In order to enter the systemic circulation and reach intended therapeutic targets 
throughout the body, SC injected biopharmaceuticals must be absorbed, presumably by 
uptake into blood or lymph capillaries 11,12. Besides specific receptors possibly being 
present on cells at or near the injection site, uptake into the circulation appears to be 
dictated by the physicochemical properties of the molecule such as hydrodynamic 
radius, net charge, and hydrophobic characteristics 13. A commercially acceptable 
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biopharmaceutical product is typically stable for two years at 5 ºC and has a high drug 
concentration to allow for a less than 1 cc injection volume; formulations are commonly 
at pH 5-6.5 and contains stabilizing excipients such as surfactants (e.g. polysorbates), 
poly-alcohols (e.g. mannitol), tonicifiers (e.g., salts and sugars), and sometime a 
preservative. Over a time frame of minutes to hours after SC injection, the 
biopharmaceutical will experience potentially stressful events; sometimes including a 
transition through its isoelectric point as the local environment shifts from conditions of 
the drug product formulation to that of the hypodermis as the SC injection site regains 
its homeostatic state. Diffusion of a biopharmaceutical from the SC injection site may 
also be affected by biophysical changes induced by this transition and interaction(s) 
with extracellular matrix (ECM) components. Efforts made to disorganize the ECM 
environment and improve the outcome of SC injections support the criticality of 
interactions with non-cellular ECM elements affecting the overall fate of a SC injected 
biopharmaceutical 14,15. Thus, we have hypothesized that a primary factor driving SC 
bioavailability achieved for a given formulation involves the stability of the 
biopharmaceutical at physiological conditions and its interactions with ECM components. 
We have established a novel in vitro system to model these early events and to simulate 
dynamic processes imposed on a biopharmaceutical as it transitions from a drug product 
formulation to the physiological conditions of the hypodermis. Our approach utilizes 
current information on the physiological properties of the hypodermis for factors such as 
ECM components, pH, ionic composition, interstitial pressure, and temperature 16. While 
the hypodermis also contains adipocytes and a sparse distribution of fibroblasts and 
macrophages, the high concentration at which most biopharmaceutricals are 
adminstered would overwhelm the capacity of these cells to exert a significant effect, 
magnifying the potential impact of these acellular components. In this report we 
present a series of studies using this in vitro subcutaneous injection site simulator 
system, termed “Scissor”, to model some of the events that might affect the fate of a 
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biopharmaceutical formulation components following a SC injection. Real-time 
measurements were made to monitor the status of the injection chamber compartment; 
the extent of a biopharmaceutical released into the infinite sink was determined in 
samples removed at specific times. The tractable nature of Scissor allows for the 
identification of specific factors that could affect the diffusion or stability of a 
biopharmaceutical after its introduction into the injection chamber and further, to 
assess the impact of formulation changes with the aim of developing a more rational 
formulation selection strategy for a biopharmaceutical that includes events that might 
occur after SC injection.  
MATERIALS AND METHODS 
Materials  
Buffers were made using NaCl, KCl, CaCl2, MgCl2, NaHCO3, K2HPO4, Na2HPO4 and Na2SO4 
purchased from Sigma (Gillingham, UK). Acetonitrile, pyridine, ethanol, m-cresol, acetic 
acid, and hydrochloric acid were of HPLC quality and purchased from Sigma (Waltham, 
MA, USA.).  Hyaluronic acid (HA) sodium salt isolated from Streptococcus equii with an 
average molecular weight of 1.5 to 1.8 MDa was obtained from Sigma (Gillingham, UK). 
Hyaluronidase (HAdase) isolated from bovine testes, fluorescently labelled dextrans, 
methylene blue, 4-aminofluorescein and 3-(3-Dimethylaminopropyl)-1-ethyl-
carbodiimide and citric acid were all purchased from Sigma (Gillingham, UK). Bradford 
reagent, Pierce Slide-a-lyzer dialysis cassettes, Biodesign 14,000 molecular weight cut-
off dialysis tubing, and phosphate buffered saline (PBS) tablets were purchased from 
Fisher (Loughborough, UK). The Dermaroller™ device was purchased from AestethiCare 
(Wetherby, UK). Water was reverse osmosis purified (Millipore, France). The monoclonal 
antibodies anonymized as mAb 2, mAb F, mAb T and mAb A were supplied by 
Genentech, Inc. (South San Francisco, USA). Insuman Comb 50 (Sanofi Aventis) was 
purchased from AAH Pharmaceuticals (Coventry, UK). Recombinant human insulin (100 
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IU/mL) obtained from Sigma (Gillingham, UK) was formulated at pH 4 or at pH 7.4 in 0.1 
M citric acid or 0.2 M Na2HPO4 buffers, respectively. In addition, each insulin 
formulation contained 16 mg/mL glycerol, 2.5 mg/mL m-cresol and 0.015 mg/mL Zn2+; 
all from Sigma (Gillingham, UK). 
Methods 
Fluorescent labelling of HA  
Hyaluronic acid was fluorescently labelled following the protocol of Ogamo et al 17. 
Briefly, 200 mg of sodium salt of hyaluronic acid was dissolved in 20 mL of 3:1 (v/v) 
mixture of 1M HCl and pyridine. 114 mg of 5-aminofluorescein (5-AF) was dissolved in 4 
mL of the same solvent and the solution was then added to the HA solution. The pH of 
the mixture was adjusted to pH 7.4 with 12 M HCl. 0.34 g of 3-(3-Dimethylaminopropyl)-
1-ethyl-carbodiimide HCl was then added to the reaction mixture while the pH was 
maintained at 7.4 by addition of 6M HCl. The reaction mixture was stirred in room 
temperature for one hour. To purify the fluorescent-HA, the reaction mixture was 
dialysed against 1 L of cold water for 24 h followed by a wash with 100 mL of cold 
ethanol, which was then dissolved in 100 mL of deionised water and freeze-dried. The 
resulting solid was reconstituted in water at 5 mg/mL for use.  
Description of the in vitro system 
Transparent 14 kDa MWCO dialysis tubing (Biodesign, Carmel, NY USA) was modified by 
puncturing a series of holes of approximately 150 µm by 50 µm in a grid pattern of 3mm 
x 3 mm using a stainless steel fine bore Dermaroller™ microneedle roller device. A Slide-
a-lyzer® dialysis cassette was disassembled and the original membranes removed. Holes 
were drilled into the plastic frame of the dialysis cassette to allow replacement of the 
membranes with the modified Biodesign dialysis membrane and securing it in place using 
plastic screws and nuts. Holes drilled into the cassette were also used to facilitate the 
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introduction of a pH probe and a needle for introduction of test formulations. The 
cassette was then filled with a physiological buffer containing HA at a final 
concentration of 1, 5, or 10 mg/mL. The physiologic buffers was composed of 6.4 g 
NaCl, 0.09 g MgCl2·6H2O, 0.4 g KCl, 0.2 g CaCl2 and 2.1 g NaHCO3 in 1 L H2O CO2, having 
a calculated osmolarity of ~ 280 mOsm/L, as described by Kay et al 18.  
A glass beaker containing 300 mL of the physiological buffer solution that was heated to 
and maintained at 34ºC, and stabilized at pH 7.4 with gaseous CO2, was placed in a 
Milton Roy Spectronic 601 spectrophotometer (Pont-Saint-Pierre, France). The modified 
dialysis cassette was positioned inside the beaker so that light path of the Milton Roy 
Spectronic 601 spectrophotometer could be used to monitor light transmittance at the 
simulated injection site within the cassette. A micro pH probe (Orion Micro, Thermo 
Scientific, Waltham, MA) connected to a Hanna Instruments HI3220 pH meter 
(Woonsocket, RI, USA) was placed into the cassette to be adjacent to the site of an 
introduced biopharmaceutical formulation but not in the spectrophotometer light path. 
The pH meter and spectrophotometer were connected to a computer and the 
measurement readings from both instruments were monitored in real-time during an 
experiment and recorded using a LabVIEW program (National Instruments Corporations, 
Austin, TX). To determine time-concentration profiles of a chemical species reaching 
the infinite sink buffer bath from the cassette, a baseline sample was taken from the 
buffer bath prior to the introduction of a 0.5 mL formulation into the injection site using 
a syringe and a suitable gauge hypodermic needle. Subsequent aliquots were taken from 
the buffer bath at selected time points.  
Analytical methods 
Sample separation by size exclusion high performance liquid chromatography (SE-HPLC) 
using the mobile phase of 0.2 M potassium phosphate buffer at pH 6.2 with 0.25 M KCl 
pumped at a flow rate of 1 mL/min and detection at 214 nm was used to analyze mAb 
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samples; samples (50 µL) were injected into a 300mm x 7.8 mm I.D., 3 µm particle size, 
Yarra-3000 column (Phenomenex Ltd, Macclesfield, UK) maintained at 25ºC. 
Insulin was detected at 214 nm using the HPLC method specified by the Pharmacopoeia 
19. Briefly, a Thermo Scientific Acclaim 120 C18 reversed-phase column with a particle 
size of 5 µm, inner diameter 4.6 mm and a length of 250mm column (Fisher, 
Loughborough, UK) was used for the analysis at room temperature. Mobile phase A 
consisted of 28.4 g/L anhydrous sodium sulfate in deionized water (pH 2.3) and mobile 
Phase B consisted of 55 parts of mobile phase A and 45 parts of acetonitrile. The final 
mobile phase was prepared by mixing 42 volumes of mobile phase A and 58 volumes of 
mobile phase B. Samples were injected as 20 µL volumes.  
Pressure measurements within the injection chamber were conducted with a needle tip 
pressure transducer from Gaeltec Devices (Dunvegan, UK). Viscosity measurements were 
performed on 70 μL samples using an Physica MCR 501 concentric cylinder cone and 
plate rheometer (Anton Paar, Graz, Austria) using the CP-25-1 measuring cell with a 25-
mm diameter and 1.007° angle. Samples were protected from evaporation and 
maintained at 25 ± 0.1°C using an Anton Paar H-PTD200 Peltier system. Sample 
viscosity, reported as the average of stabilized viscosity measurements from three 
independent replicates, was determined by measuring torque every second for 60 s 
using a constant shear rate of 1000 s−1. Anton Paar RheoPlus software was used for 
sample analysis and data reporting. 
Human clinical trial data 
Human mAb bioavailability date was obtained from studies that were conducted in 
accordance with the International Conference on Harmonisation E6 Guideline for Good 
Clinical Practice and approved by local internal review boards. Patients provided 
written informed consent prior to study inclusion.  
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Data analysis 
Curves were fitted to the time-concentration profiles obtained for the different 
formulations with SigmaPlot software v12.5 (Systat Software Inc. London, UK) using 
equation 1: 
 Equation 1. 
This model results in Bmax and t1/2 parameters for the maximum diffused fraction and 
half-life of diffusion of analytes, respectively. To enable meaningful comparison, the 
highest recovery for each of the mAb formulations was set to 100% and the lower 
recoveries normalized to values proportional to this standard. Data is presented as mean 
± standard deviation (SD).  
RESULTS AND DISCUSSION 
Organization of the Scissor system 
Scissor was designed to recreate, in an in vitro setting, dynamic events that could affect 
the fate of a biopharmaceutical formulation delivered by subcutaneous (SC) injection in 
vivo. These dynamic events reflect the environmental changes that would occur as the 
SC injection site transitions from the drug product to the physiological conditions of the 
human hypodermis. This transition involves changes in pH, temperature, and ionic 
components with a loss of excipients transient pressure changes due to volume 
introduction - events that occur over a time frame of minutes to hours (Fig. 1A). Given 
these complexities, the Scissor system was developed with several components. A 
beaker containing 300 mL of a physiological media emulates the ion composition and pH 
of the hypodermis and functions as the infinite sink of the body. While the exact ionic 
composition of the hypodermis is difficult to know precisely, it has been reported to be 
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similar to serum 20,21, thus, the buffer used reflects this information available in the 
literature.   
A modified dialysis cassette used as a chamber to emulate the SC injection site was 
positioned within the beaker containing the physiological media. The injection chamber 
was designed in two formats, one for injection volumes of <100 µL and the other for 
volumes of up to 1 mL. The injection chamber was designed so that it could be filled 
with different combinations and concentrations of extracellular matrix (ECM) 
components. The pH inside the injection chamber could be continuously monitored using 
a needle pH probe positioned in close approximation to the site of sample introduction 
achieved using a syringe and a needle combination consistent with the clinical use of 
these formulations (Fig. 1B).  
The injection chamber/infinite sink compartment components were positioned in the 
single-beam spectrophotometer in such a way as to allow temperature control of the 
contents through the use of a heating mantle, gentle mixing using a magnetic stirring 
bar, and measurement of transmitted light at a selected wavelength (Fig. 1C). The 
system was maintained at approximately 34°C, which is the average hypodermis 
temperature 22 and the physiological media in the infinite sink was maintained at pH 7.4 
by the addition of CO2 (g). To monitor the amount and status of materials leaving the 
injection chamber the over time, 0.75 mL aliquots of solute bath chamber were taken at 
selected time points and assayed by HPLC protocols.  
A 	 B 	 C 	 
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Figure 1. Dynamic events in the hypodermis following the injection of a biopharmaceutical 
formulation can be modeled using a modified dialysis system. A) Diagram of components and 
events denoting the exchange of small molecules (salts, sugars, and other excipients), buffer 
(transition to a bicarbonate-based environment), equilibration of temperature and pressure, and 
potential interaction with extracellular matrix (ECM) components. B) Cartoon depicting 
arrangement of positioned probes to continuously monitor pH inside and outside of the sample 
injection chamber and positioning of light path (crenulated circle) in a large solute bath chamber 
that emulates the infinite sink of the body. C) Cartoon depicting arrangement of injection 
chamber/infinite sink compartment in a single-beam spectrophotometer that allows for 
temperature control and stirring of the large bath contents. The numbering in B) and C) follows 
the legend shown in C). 
Component Evaluation  
Movement of a biopharmaceutical from the injection chamber into the infinite sink 
compartment would emulate migration of the drug from the injection site into the 
circulation as a result of local diffusion and subsequent uptake into blood capillaries 
and/or lymph capillaries in vivo. To model these two mechanisms of clearance from the 
SC injection site using the Scissor injection chamber, we used a 14 kDa MWCO dialysis 
membrane modified by a grid pattern of regularly spaced holes generated by the 
penetration of a Dermaroller™ microneedle roller device to represent a distribution of 
absorption points into lymph and blood capillaries, with a background of small molecular 
weight excipients diffusing through pores in the dialysis membrane (Fig. 2A). A linear 
correlation was observed between the log molecular weight for molecules ranging from 
300 to 2,000,000 Da vs. the passive transport rate across the modified dialysis 
membrane (Fig. 2B). The molecular weight range selected for these studies covered the 
range anticipated for most biopharmaceuticals and excipients currently considered for 
SC injection.   
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We next evaluated the retention of hyaluronic acid (HA), a prominent component of the 
extracellular matrix (ECM), within the injection chamber. We tested this by following 
the release of HA labeled with 5-aminofluorescein (5-AF) using hyaluronidase (HAdase) 
from the Scissor injection cassette. HA at 10 mg/mL was combined with a small amount 
of HA modified with 5-AF (<0.1%) and placed in the injection chamber. Release of 5-AF 
from the injection chamber, prepared using the previously described modified dialysis 
membrane, was monitored over time using an Omega Fluostar plate reader (Fig. 2C). 
After 1 h, only trace amounts of 5-AF were measured in the infinite sink compartment, 
suggesting that the membrane used in the Scissor system effectively restricted the 
efflux of HA from the injection chamber. As a positive control, 2.5 mg of HAdase was 
injected in a 100 L volume of physiological buffer solution into the injection chamber 
after one h of monitoring HA diffusion, which resulted in a steady release of 5-AF into 
the infinite sink chamber (Fig. 2C).  
Finally, we considered the interstitial pressure (IP) of the hypodermis as an element 
that might affect events associated with SC injection site outcomes. Two factors 
dominate hypodermis IP: fluid dynamic pressure associated with an increased volume in 
a defined space and colloidal osmotic pressure exerted by poly-ionic materials in 
proximity to a semipermeable barrier 16. Measurements made of the hypodermis IP have 
suggested this value to between 10-15 mm Hg 23,24. We used the hydrostatic pressure 
produced by the fluid of the infinite sink against the membrane of the injection 
chamber to emulate physiological pressure conditions; the dialysis cassette was placed 
at a depth in the beaker bath to produce a pressure in the range of 10 mm Hg as 
measured with a needle probe pressure transducer (Fig. 2D). Pressure measurements 
within the injection chamber were conducted with a needle tip pressure transducer 
from Gaeltec Devices.  Injection of a volume relevant to a biopharmaceutical 
formulation produced only a minor and transient pressure shift within the dialysis 
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cassette (Fig. 2D). 
 
A B  
C   D	  
 
Figure 2. Characteristics of dialysis membrane and dialysis cassette matrix components. A) 
Optical characterization of Dermaroller™-modified dialysis membrane showing the nature of an 
introduced pore. Scale bar = 200 µm.  B) Macromolecular flux in terms of diffusional half-life (t1/2) 
across the Dermaroller™-modified dialysis membrane was linear across a wide range that is 
relevant for most biopharmaceuticals. C) Impact of hyaluronidase (HAdase) on retention of 
labeled HA in the injection chamber. Release of 5-aminofluorescein that was chemically coupled 
to HA was monitored by detection of fluorescence in the infinite sink bath over time with HAdase 
being added at 60 min. D) Pressure measured within the injection chamber dialysis cassette 
before and after an injection of 0.5 mL of water at 15 sec. The data represents average (n=3) ± 
S.D. 
Evaluation of insulin formulations using the Scissor system 
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Human insulin was formulated at acidic conditions and with the excipients m-cresol and 
Zn2+, similar to commercial products of this biopharmaceutical 25, and injected into the 
Scissor system injection chamber that lacked ECM elements (Fig. 3A). In this case, m-
cresol was observed to leave the injection chamber rapidly, essentially being completely 
absent in the injection chamber after ~ 30 min. We observed that the pH of the 
injection chamber dropped from neutrality to ~3.5 very rapidly and this change 
correlated with a striking decrease in injection chamber clarity, suggesting insulin 
precipitation at the injection site (Fig. 3A). The pH within the injection compartment 
approached neutrality by ~75 min, correlating with the release of insulin into the 
infinite sink. These data suggest that insulin formulated in this way rapidly precipitates 
at the SC injection site and that m-cresol can leave the injection site prior to the 
recovery of insulin solubility and release into the infinite sink. From this data, one could 
conjecture that some proteins, such as insulin in a crystalline form, could be retained at 
the SC injection site until conditions favor protein solubility, but that this time return to 
soluble conditions may occur in the absence of stabilizing excipient(s) present in the 
drug product.  
We next questioned the potential role of ECM elements to affect the release of insulin 
from the injection chamber.  Insuman Comb 50, an insulin suspension formulation 
designed to provide rapid and intermediate pharmacological actions on blood sugar 
regulation, was injected into chambers with or without 5 mg/mL HA (Fig. 3B). The 
release profile of insulin was slowed by the presence of HA in the injection chamber, 
but the extent of insulin release reached a similar diffused fraction asymptote both with 
and without the presence of HA. These results suggested that the increased viscosity 
due to the presence of a HA may slow the release of insulin from the injection chamber 
but that the extent of insulin release is ultimately not limited by potential interactions 
with this ECM element. The incomplete diffused fraction (~60%) of the insulin in both 
cases is most likely due to the slow and incomplete dissolution of the crystalline insulin 
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in the Insuman Comb 50 formulation. Further, we observed a greater variability in the 
diffused fractions obtained for the Insuman Comb 50 formulation when it was injected 
into cassettes lacking HA than into those containing 5% HA. We believe this was because 
the presence of ECM components the cassette provides a resistance of spreading for the 
injected formulation, resulting in more consistent outcomes. 
A  B  
 
Figure 3. Insulin formulation outcomes in the Scissor system. A) A composite graph showing 
real-time dynamic changes in pH and percent light transmission (%T) as an index of protein 
solubility in the injection chamber as well as total amount of an excipient observed in the infinite 
sink for a test insulin formulation over time. Note how the tracings demonstrate injection 
chamber acidification and protein precipitation upon its introduction. Protein solubility recovered 
as the pH in the injection chamber approached neutrality, but at a time when the excipient m-
cresol had already left the injection chamber. B) Release rates of insulin from the injection 
chamber following introduction of Insuman 50 in the presence or absence of 5 mg/mL HA. The 
data represents average (n=3) ± S.D. 
Evaluation of human monoclonal antibody (mAb) formulations using the 
Scissor system 
Four human mAbs having distinct physicochemical properties and formulations (Table 1) 
were examined. Importantly, previous clinical use of these antibodies has generated 
bioavailability information following SC injection (in-house data generated by 
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Genentech): mAb A (77%) >mAb 2 (50-70%) > mAb F (44%) ~ mAb T (42%). The diffused 
fraction for all of these mAbs from the injection chamber in the absence of HA was 100% 
(Fig. 4). We examined the release of these mAbs from the injection chamber into the 
infinite sink compartment as a correlative to release from the SC injection site. 
Potential interactions of these mAbs with HA was evaluated by examining their 
movement from the injection chamber to the infinite sink compartment (release 
profiles) with different levels of HA present in the injection chamber. To enable 
meaningful comparisons, the highest recovery obtained for each mAb formulation was 
considered as 100%, with lower recoveries normalized to this value (Fig 4). 
Table 1. Properties of the monoclonal antibody (mAb) proteins and formulations 
used in these studies. 
mAb Name aIsoelectric 
Point (pI) 
bCharge 
at pH 7.4 
Concentration 
in mg/mL 
Formulation 
and pH 
cFormulation 
Viscosity  
mAb A 
 
6.1 -5.3 
125  30 mM 
Histidine-based 
buffer, pH 5.7 
7 
mAb 2  
 
7.6 +1.0 
125  30 mM 
Histidine-based 
buffer, pH 6.0 
80 
mAb F 
 
8.7 +9.0 150  
200 mM 
Arginine-based 
buffer, pH 5.5 
12 
mAb T 
 
9.1 +13 150  
200 mM 
Arginine-based 
buffer, pH 5.5 
5 
aMeasured by isoelectric focusing. bTheoretical calculation. cDetermined using a cone and plate 
rheometer and presented as centipoise. 
The diffusion profiles for each mAb were affected to varying extents by increased HA 
concentrations in the injection chamber. This is shown in Figs. 4A-D where the time-
concentration diffusion profiles fitted to sampling data points based on Equation 1 for 
the different mAbs are presented. The diffused fraction of A (Fig. 4A) was not 
correlated with HA concentration: 5 mg/ml HA content resulted in a lower diffused 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Kinnunen et al  In vitro model of the SC injection site 
17 
 
fraction than 10 mg/ml HA content (~60 and 80%, respectively). These results suggest 
that factors other than HA interactions may dominate events that control the release of 
this antibody from the SC injection site. Data collected for mAb 2 (Fig. 4B) showed a 
decrease in diffused fraction that correlated with increased HA concentration: 0 (~100% 
diffused) to 1mg/ml (~90%) to 5 mg/ml (80% diffused), and 10 mg/mL HA resulting to a 
diffused fraction of ~60% by 6 h.  
The addition of HA at 1 mg/ml into the cassette did not hinder the diffusion of mAb F 
(Fig. 4C). However, addition of HA at 5 and 10 mg/ml concentrations resulted in the 
diffused fraction decreasing to ~60%.  Studies with mAb T (Fig. 4D) showed a gradual 
decrease in diffused fraction over the HA concentrations tested; its value of ~40% 
diffused fraction at 6 h at 10 mg/ml HA was similar to that observed for mAb F. It should 
be noted that triplicate runs yielded highly reproducible results for all HA concentration 
conditions tested for mAb T and mAb F, suggesting that the basis for antibody 
interaction with this ECM element was consistently replicated for each test performed 
(Figs. 4C, 4D). As mAb T and mAb F are positively charged at pH 7.4 (Table 1), the 
consistency of the data from run-to-run indicate that the retention of these mAbs at the 
injection site in the presence of HA, which is negatively charged at a physiological pH, 
could involve electrostatic interactions.  
Diffused fraction data obtained for mAb2 without HA or where HA was present at 1 
mg/mL were very reproducible but injection of mAb2 into 5 mg/mL HA showed greater 
variability (Fig. 4B). Further, mAb 2 tested in 10 mg/mL HA was even more variable than 
the data set obtained for 5 mg/mL HA and was repeated four times. As this antibody is 
nearly neutral in charge at pH 7.4 (Table 1), the variability could be due to the 
weakness of electrostatic interactions between the protein and the HA; small changes in 
the pH for example may result in a significant alteration of the mAb surface charge. 
Interestingly, these results also correlate with findings from an in vivo study in mini-
pigs, where a higher pI of an mAb, i.e. higher positive charge at physiological pH, 
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resulted to lower bioavailability 5.Furthermore, while mAb A showed reproducible 
diffused fraction outcomes when tested without HA, the variability in diffusion fraction 
for this antibody was remarkable for all concentrations of HA tested, requiring five 
replicates to be performed (Fig. 4A). In contrast to the other antibodies examined in 
these studies, mAb A failed to show an HA concentration-dependent interaction profile, 
even though the overall extent of release from the injection chamber was diminished by 
the presence of HA. Interestingly, this mAb has a net negative charge at neutral pH, and 
therefore the high variability of our results could reflect electrostatic repulsion between 
HA and the mAb A molecules whereby release of the antibody from the cassette is 
dictated by distribution following injection to a greater extent than when antibody-
matrix interactions occur through electrostatic attraction. 
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Figure 4. Diffusion of various mAbs from the Scissor system injection chamber containing 
different concentrations of hyaluronic acid (HA). All mAbs were introduced into the injection 
chamber as 500 mL of a formulation with a protein concentration from 125 – 150 mg/mL. The 
extent of mAb released (A-D; mAbs A, 2, F, and T, respectively) from the injection chamber was 
determined by SE-HLPC analysis of samples collected from the infinite sink chamber at specific 
times.  Data obtained when the injection chamber contained physiological buffer only (filled 
circles), or physiological buffer containing 1 mg/mL (open circles), 5 mg/mL (filled triangles), or 
10 mg/mL (open triangles) HA are shown as mean values ± SD. N=3 except where noted otherwise 
in the legend.  
To further study the significance of HA interactions on the extent of mAb release, 
HAdase was injected into the injection chamber 120 min after the introduction of mAb 
T. Subsequent increase in the diffused fraction of mAb T was observed (Fig. 5A). This 
finding, in conjunction with data showing increased HA diffusion from the injection site 
following HAdase addition (Fig. 2B), confirms that non-specific interactions between 
mAb T and HA indeed influence the extent of its release.  
Introduction of a long-acting insulin formulation resulted in a rapid lowering of the 
injection chamber pH and the formation of a precipitate that lowered the %T of the 
system; transient events where the recovery of physiological pH correlated with an 
increase in %T and insulin release from the injection chamber (Fig. 3). We questioned 
whether the moderately acidic formulations of the mAbs tested herein would also 
demonstrate a decrease in %T and pH transition that might correlate with decreased 
fraction release outcomes. All of the mAb formulations tested exhibited only a 
moderate drop in the injection chamber pH with a fairly rapid recovery and none of 
these formulations demonstrated a reduction in %T in the injection chamber. An 
example outcome of these studies is shown for mAb T under the conditions of 5 mg/mL 
HA in the injection chamber that resulted in a transient depression in pH (from 7.4 to 
~6.8) and no appreciable decrease in %T (Fig. 5B).  
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A  B  
 
Figure 5. Effect of hyaluronidase (HAdase) on mAb release from in injection cassette. A) 
Addition of HAdase at 2 h into the cassette containing 5 mg/mL HA increased the released fraction 
of mAb T (inverted triangles) compared to reference experiments at 5 mg/mL HA where no 
HAdase was added (open circles). For comparison, to illustrate the significance of presence of HA 
into the diffused fraction of mAb T, the release profile for buffer only experiment is also shown 
(black dots). The data represents mean from 3 experiments. For clarity of presentation error bars 
have been omitted. B) %T and pH for mAb T formulation with 5 mg/mL HA in the cassette. Data 
points ±S.D, n=3. 
We next explored parameters that could be used to correlate the properties of mAb 
release from the injection chamber with the %BA measured for these proteins in 
patients. In plotting the fraction of dose released at the 6 h plateau for the different HA 
concentrations tested, a pattern of HA dependence for these four mAbs emerged that 
showed a correlation between in vivo %BA and the diffused fraction of the mAbs, where 
10 mg/mL HA was included in the injection chamber (Fig. 6A). Variability of Scissor 
system outcomes must be comparable to the variability of in vivo %BA outcomes for such 
a correlate to be meaningful. We performed a t-test and an f-test analysis; there was no 
statistically significant difference between the distributions or variability of these data 
(note that variability data for mAb 2 in patients was not available and thus not 
included). A linear regression analysis showed a goodness of fit (R2 = 0.93 and a slope of 
~1 that demonstrated a good correlation between 10% HA outcome and %BA outcomes in 
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patients for these four mAb (Fig. 6B). Thus, our data supports the potential role of HA 
interactions as an ECM element that could affect the absorption of these four human 
mAbs from a SC injection site. 
  
Figure 6. Correlation of injection chamber HA concentration with diffused fraction release 
and human bioavailability. A) Fraction release of mAbs from the injection chamber at 6 h as a 
function of HA concentration (mg/mL) and comparison to %BA values observed in humans. B) 
Linear regression analysis between Scissor values and human %BA outcomes presented in A).  
CONCLUSIONS AND PERSPECTIVES 
Despite extensive clinical use, the exact mechanism underlying subcutaneous absorption 
of protein and peptide drugs is still poorly understood, with their absorption in patients 
being relatively slow and mostly incomplete 26,27. Presently, there is no animal model 
that can reliably predict clinical pharmacokinetics 28. We have begun to address this 
deficiency by developing an in vitro system (Scissor) that uses a dialysis membrane-
restricted compartment that contains selected and defined ECM elements present in the 
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hypodermis, to model potential events and interactions that might occur following SC 
injection of a biopharmaceutical formulation. This system establishes physiologically 
relevant conditions for temperature and pressure, while allowing for the dynamic 
transistion of environmental condtions of a biopharmaceutical from its drug product 
formulation to conditions perceived to be present in the hypodermis 16.  
Many of the previous studies examining biopharmaceutical uptake following SC injection 
have focused on defining the relative contributions of lymph versus blood uptake from 
hypodermis 26,27.  The Scissor system is focused on events within the hypodermis and not 
the route by which materials might leave the SC injection site. The dialysis membrane 
used in the Scissor system was prepared in a way to emulate the mixture of diffusion 
and blood/lymph capillary uptake that define the major mechanisms involved in 
movement of a biopharmaceutical from a SC injection site and thus does not attempt to 
discrimintate between the two; this membrane was shown to provide linearity relative 
to molecular weight. The injection chamber can be prepared with different mixtures of 
acellular ECM components that are retained by this dialysis membrane for the duration 
of these studies and used to assess the impact of these materials on a SC injection 
formulation in a tractable manner.  
Our initial studies have demonstrated how excipients can leave the injection chamber 
before the biopharmaceutical, how a biopharmaceutical can initially precititate after 
injection and then release from the injection site after equlibration following pH 
recovery that leads to resolubilization, and how an ECM element can slow or modify the 
release of a biopharmaceutical at the injection site. Studies involving insulin and a 
series of monoclonal antibodies were described in this report, but other peptides and 
protein therapeutics as well as small molecule drug formulations designed for sustained 
release could be assessed using the Scissor system. With regard to the latter, we are 
now fitting the Scissor system with a digital camera to allow visual characterization of 
formulation performance. 
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The Scissor system allows monitoring the rate and status of individual components of a 
formulation to examine their fate after introduction into an acellular hypodermis-like 
environment that returns to the homeostatic conditions of the hypodermis. Importantly, 
clinically-relevant of formulation volumes and drug doses can be introduced into the 
injection chamber for testing. Sampling of the infinite sink compartment allows 
information to be gathered regarding the extent and condition of materials leaving the 
injection chamber. Monitoring events within the injection chamber can be performed 
using visible light spectroscopy as we have identified, as HA is optically clear. Although 
removal of injection chamber material at specific times to assess events occuring at this 
artificial injection site can provide valuable information, we have focused on methods 
of non-invasive assessment of the injection chamber. The current version of the Scissor 
system is capable of providing real time information of events within the injection 
chamber and we aim to develop other integrated tools to provide additional real time 
data, such as Raman spectroscopy. 
The Scissor system is not intended to reproduce the entirety or complexity of events 
that occur at the SC injection site or to directly replicate individual components of the 
hypodermis. Further, the exact composition of ECM elements in the hypodermis is 
unclear. HA concentration in the human dermis has been determined to be 0.2 mg/g 29, 
which is probably less that that present in the hypodermis; it is unclear, however, if HA 
levels in the hypodermis reach 10 mg/mL, as used in our studies. Importantly, Scissor is 
designed to provide a tractable system where specific interactions can be explored and 
these studies have supported the use of an in vitro format using up to 10 mg/mL of HA 
to discern potential interactions for this ECM component. The system is not sterile and 
can realistically be run under physiological conditions for only up to about 12 h. Longer 
studies can be performed with the addition of a bacterial static agent, but this addition 
compromises the physiological basis of the method and the outcomes must be 
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considered accordlingly. The acellular nature of the current Scissor system limits the 
acquitision of information regarding local cell-based metabolic events that might at the 
injeciton site for highly potent biopharmaceuticals that are admininstered at low doses 
30.  
One of the first steps in the development of a biopharmaceutical involves the 
identification of a formulation that ensures a multi-year shelf-life required for 
commercial success. Often, several types of formulations can provide the desired shelf-
life stability and the ultimate selection between these must be made based upon in vivo 
animal studies that may or may not reflect subsequent outcomes in man 31. There is no 
method to compare multiple formulations that will predict pharmaokinetics and other 
clinical outcomes and clinical testing of multiple formulations is prohibitively expensive. 
The Scissor system can provide a useful in vitro rapid screening tool to assess potential 
injection site outcomes, as an early step in formulation development and selection that 
would reduce animal use, expedite the formulation selection process, and provide a 
tractable method for the optimization of formulations. Overall, our data suggest the 
Scissor system to provide a robust, rapid, and tractable in vitro system to model 
potential events following SC injection. Ultimate benefit of the Scissor system to 
medicine could come in several forms: expedited testing of candidate formulations 
without using animals to rapidly and efficiently identify those most appropriate for 
further pre-clinical screening, rational improvements in therapeutics and formulations 
designed for SC injection identified through a reproducible and systematic screening 
effort, and the possibility of defining parameters to assess consistency of performance 
for a marketed formulation administered by SC injection. We believe such a tool could 
also lead to hypothesis-driven testing to better define specific aspects of hypodermis 
biology.  
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